BSP Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BSP Pharmaceuticals is a specialized CDMO offering integrated development and manufacturing services for sterile injectables, with a core expertise in high-potent and cytotoxic oncology drugs, including ADCs. Its key differentiators are segregated, high-containment, and explosion-proof facilities on a single campus, enabling services from conjugation to fill-finish for ADCs. The company supplies over 80 countries and supports clients with regulatory filings, lifecycle management, and a focus on lipid-based and sensitive formulations. BSP positions itself as a critical partner for innovators in oncology and complex therapeutics.

Oncology

Technology Platform

High-containment, explosion-proof manufacturing facilities for cytotoxic and high-potent compounds. Integrated platform for Antibody-Drug Conjugate (ADC) conjugation and fill-finish. Expertise in lipid-based formulations for sensitive molecules (peptides, proteins, oligonucleotides).

Opportunities

Strong growth in the ADC and high-potent oncology drug markets drives demand for specialized CDMO services.

The trend towards outsourcing by biopharma innovators and the complexity of new modalities (oligonucleotides, nanomedicines) expands the addressable market.

BSP's integrated, single-site ADC services offer a key advantage in a capacity-constrained segment.

Risk Factors

Revenue is dependent on the clinical and commercial success of client programs, creating pipeline concentration risk.

Intense competition from larger, global CDMOs and regulatory/compliance risks inherent in sterile manufacturing pose significant challenges.

Any operational disruption or quality failure could severely damage its reputation and client relationships.

Competitive Landscape

BSP competes in the sterile injectable and high-potent drug CDMO space against large global players like Lonza, Catalent, and Thermo Fisher Scientific, as well as specialized peers such as Pfizer CentreOne, Vetter, and Recipharm. Its differentiation lies in its focused high-containment expertise, integrated ADC platform, and single-campus segregation for cytotoxic and non-cytotoxic processing.

More companies in Drug Delivery & Formulation →More companies in Italy →